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Rac GTPase activating protein 1 (RacGAP1) can regulate cytokinesis and cell differentiation. The oncogenic role of RacGAP1 has been partially studied in gastric cancer, colorectal cancer, and breast cancer. In the present study, we endeavor to evaluate its expression and functions in epithelial ovarian cancer (EOC). We retrospectively collected the clinicopathological information of 117 patients who underwent curative surgery for EOC. Expression of RacGAP1 protein in primary tumor tissues was evaluated by immunohistochemistry, which was significantly associated with tumor pathological grade, tumor stage, and lymph node metastasis. Patients with lower RacGAP1 level had a longer survival time and lower recurrence risk. Multivariate results identified the independent prognostic role of RacGAP1 for both recurrence and survival in EOC patients. Cellular studies showed that RacGAP1 can positively regulate the activation of RhoA and Erk proteins. In addition, wound healing assay and Transwell assay found that RacGAP1 can up-regulate the migration and invasion process of EOC cells, respectively. In all, our results not only confirmed the prognostic role of RacGAP1 for recurrence and survival in EOC patients, but also highlighted its possible potency for drug development.
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| INTRODUCTION
Ovarian cancer is one of the most lethal gynecological malignancies, and during the past decades its incidence has been increasing. 1 More than 70% of ovarian cancer patients are diagnosed at an advanced stage as a result of its asymptomatic characteristics and lack of reliable early diagnostic detection. 2 Epithelial ovarian cancer (EOC)
accounts for approximately 80% of all ovarian cancers. 3 Despite great achievements in the development of therapeutic methods, the 5-year survival rate of EOC patients remains at approximately 30%. 4 In fact, most EOC patients will ultimately develop disease recurrence. 5 EOC originates from malignant transformation of the ovarian surface epithelium as a result of an accumulation of genetic changes. 6 Therefore, understanding the molecular mechanisms of EOC progression and searching for novel biomarkers is critical for identifying early-stage patients, providing novel drug targets, and improving patients' clinical outcomes.
Rho family small GTPases are intracellular signaling molecules belonging to the Ras superfamily, including RhoA, Rac1, and Cdc42. When GTP-bound, Rho-GTPases are active and can regulate cellular responses such as cytokinesis, the cell cycle, survival and migration. 8, 9 Therefore, Rho-GTPases have been implicated in tumorigenesis. 10 As GTP is necessary for the activity of Rho-controlling the functions of Rho-GTPases. Thus, the GTPase-activating proteins (RhoGAP), which stimulate the intrinsic GTPase activity of Rho proteins and return them to an inactive GDP-bound state, 11 are generally presumed to inhibit tumorigenesis. 12 
| Cell culture and transfection
Human EOC cell lines Caov-3 and OV-90 cells were purchased from ATCC (Manassas, VA, USA). OV-90 cells were cultured in DMEM-F12 medium, whereas Caov-3 cells were cultured in DMEM medium, both supplemented with 10% FBS and antibiotics (100 U penicillin G, 100 lg/mL streptomycin sulfate). All cells were maintained at 37°C in 5% CO 2 atmosphere.
The plasmid constructs that express RacGAP1 (pcDNA-Rac-GAP1), and the negative control vector plasmid (pcDNA) were purchased from GenScript (Nanjing, China). siRNA that targeted RacGAP1 and a scrambled negative control were purchased from GenePharma (Shanghai, China) with the following sequences: 
| Western blotting
Total cell lysates were obtained by homogenization in RIPA lysis buffer (50 mmol/L Tris HCl, 150 mmol/L NaCl, 1% NP-40, 0.5% sodium deoxycholate, 1 mmol/L EDTA, 0.1% SDS) supplemented with 1 mmol/L Na 3 VO 4 , 5 mmol/L NaF, 50 lg/mL aprotinin and leupeptin. The suspension was centrifuged at 13 800 g for 10 minutes
to discard the precipitate. Protein concentrations were determined
by Bradford assay (Bio-Rad, Hercules, CA, USA), and 20 lg total protein was resolved by 10% SDS-PAGE for immunoblotting analysis.
Electrotransfer was conducted to transfer proteins onto PVDF membranes, followed by blocking and probing with the indicated primary antibodies at 4°C overnight. After incubation with the HRP-conjugated secondary antibodies (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), immunoreactivity was detected by enhanced chemiluminescence (Thermo Fisher Scientific).
| Migration and invasion assays
Migration ability of EOC cells was evaluated by using a wound healing assay as previously described with minor modifications. 
| Statistical analysis

| RacGAP1 expression and its correlation with clinical characteristics
RacGAP1 is mainly located in the cell nucleus, with slight expression in the cytoplasm ( Figure 1A,B) . Using the classification method described before, RacGAP1 was defined as low expression in 41.9%
(49/117) of cases and high expression in 58.1% (68/117) of cases, respectively. Associations between IHC staining and clinicopathological characteristics are shown in Table 1 . High expression of Rac-GAP1 was significantly correlated with poor differentiation (P = .029, Figure 1C ), positive lymph node metastasis (P = .001, Figure 1D ), advanced FIGO stage (P < .001, Figure 1E ) and existence of tumor cells in ascetic fluid (P = .020, Figure 1F ). There was no statistical difference in the expression of RacGAP1 among different tumor types (P = .726).
| RacGAP1 indicates poor OS and progressionfree survival (PFS)
To further explore the role of RacGAP1 expression as well as clinicopathological parameters in the clinical outcomes of EOC patients, Kaplan-Meier survival analyses were first carried out (Table 2 ). EOC patients with higher RacGAP1 expression had a shorter OS in comparison with those with lower RacGAP1 expression (75.0 AE 2.3 vs 44.0 AE 4.8 months, P < .001, Figure 2A ).
Other prognostic factors include lymph node metastasis, FIGO stage, and serum CA-125 level ( Figure 2B-D) . Neither pathological differentiation grade nor histological type of EOC showed statistical significance (Table 2) . Moreover, subsequent multivariate COX proportional hazards analysis determined the independence of the prognostic value of RacGAP1 expression on the OS of EOC patients (HR = 2.063, 95% CI = 1.237-3.439, P = .006, Table 2 ).
Also, positive lymph node metastasis and advanced FIGO stages were both independently correlated with shorter OS (P = .048 and P = .031, respectively). We also analyzed the PFS of the cohort by univariate and multivariate analyses (Table 3 ). In univariate Kaplan-Meier survival results, higher RacGAP1 expression (P < .001, Figure 2E ), positive lymph node status (P < .001, Figure 2F ), advanced FIGO stage (P < .001, Figure 2G ) and higher serum CA-125 level (P = .029, Figure 2H ) revealed unfavorable PFS for EOC patients. In the COX multivariate regression models, higher RacGAP1 expression was also correlated with shorter DFS (HR = 2.007, 95% CI = 1.217-3.309, P = .006) in EOC patients. Other unfavorable independent factors for PFS include positive lymph node metastasis and advanced FIGO stage (P = .147 and P = .030, respectively).
T A B L E 2 Prognostic parameters for OS in EOC patients by univariate and multivariate Cox proportional hazard model analyses
| RacGAP1 is involved in the process of cell migration and invasion
Clinical results showed that endogenous RacGAP1 expression was significantly correlated with lymph node metastasis, thus prompting us to investigate whether EOC cell migration and invasion can be affected by RacGAP1. We first tested the efficiency of RNAi in OV-90 cells ( Figure 3A) , and selected siRNA#3 for further experiments.
As shown in Figure 3B , migration ability was inhibited in OV-90 by E-H, Similarly, progression-free survival was also evaluated by plotting KaplanMeier curves. All statistical significance was compared by using log-rank test ( Figure 4A ). As expected, RacGAP1 can deactivate Rac1 protein by decreasing the level of GTP-Rac1. Interestingly, the active form of RhoA protein, GTP-RhoA, was up-regulated in EOC cells overexpressing RacGAP1. In contrast, knockdown of RacGAP1 inhibited the level of GTP-RhoA. Similarly, the activity of Erk protein, a downstream effector of RhoA, was positively correlated with RacGAP1 expression. As Erk activation is important in regulating tumor cell migration and invasion, we next tested the protein level of p-Erk in EOC tissues and found that p-Erk was highly expressed in 66 patients (66/117, 56.4%), which mainly existed in the cytoplasm (Figure 4B) . Furthermore, there was a significant positive correlation between RacGAP1 and p-Erk expressions in clinical EOC tumor tissues as determined by IHC analysis (v 2 -test, P = .033, Figure 4C ). because suppressing Rac activity is sufficient to permit RhoA activation. 30 In addition, phosphorylation of Erk protein was also positively regulated by RacGAP1 expression.
| DISCUSSION
To better explain our results, we gathered resected EOC tissue samples and carried out IHC analysis. As expected, IHC data showed a positive correlation between RacGAP1 and p-Erk expression levels.
However, we must keep in mind that the statistical correlation is not enough to define infallible signaling pathways, and further experiments are necessary to better elucidate the functional mechanisms.
In summary, our clinical and molecular findings showed that a subset of EOC patients have RacGAP1 overexpression which is associated with advanced tumor stages and poor clinical outcomes. Thus, RacGAP1 may be a novel clinical biomarker for predicting the prognosis of EOC. This is the first report to suggest a relationship between RacGAP1 and prognosis of EOC patients, and further prospective trials in clinical settings would be worthwhile. Our study may also be helpful in exploring novel therapeutic targets and improving treatment outcomes.
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